Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v2.4.1.9
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2015
Fair Value Measurements Tables  
Financial instruments carried at fair value on a recurring

 

   

March 31,

2015

    Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
 Description       (Level 1)     (Level 2)     (Level 3)  
 Assets:                        
 Marketable securities     993       -       993       -  
 Total assets   $ 993     $ -     $ 993     $ -  
                                 
 Liabilities:                                
 Warrants potentially settleable in cash   $ 13,456     $ -     $ -     $ 13,456  
 Total liabilities   $ 13,456     $ -     $ -     $ 13,456  
                                 
   

December 31,

2014

    Quoted Prices in Active Markets   Significant Other Observable Inputs   Unobservable Inputs  
 Description       (Level 1)     (Level 2)     (Level 3)  
 Assets:                                
 Marketable securities     1,975       -       1,975       -  
 Total assets   $ 1,975     $ -     $ 1,975     $ -  
                                 
 Liabilities:                                
 Warrants potentially settleable in cash   $ 8,464     $ -     $ -     $ 8,464  
 Total liabilities   $ 8,464     $ -     $ -     $ 8,464  

 

Level 3 financial assets and liabilities

 

   

Fair Value Measurements Using Significant Unobservable Inputs

(Level 3)

 
    2015     2014  
 Balance , January 1,   $ 8,464     $ 23  
 Change in fair value of Teva option     -       (23 )
 Estimated fair value of warrants assumed in merger on January 2, 2014     -       10,475  
 Estimated fair value of warrants issued in January 2014 common stock sale     -       3,696  
 Estimated fair value of warrants exchanged for common shares     (9,426 )     -  
 Change in fair value of warrants     14,418       (2,082 )
 Balance at March 31, 2015 and 2014   $ 13,456     $ 12,089